Intercell’s vaccine, which helps to prevent Japanese Encephalitis, has already been approved and launched in the USA, Europe, Canada and Australia.
Ixiaro is a modern purified, inactivated vaccine for active immunization of adults against infections caused by the Japanese Encephalitis Virus.
Ixiaro is manufactured at Intercell’s proprietary manufacturing facility in Scotland using tissue culture rather than live organisms.
Intercell said that the decision by the Swiss authorities represents another important milestone for the licensure process initiated for selected attractive market segments.
Thomas Lingelbach, chief operating officer of Intercell, said: “The Swissmedic approval is great news and another important step in the product’s global reach.”
Ixiaro vaccine was developed under a collaborative research and development agreement with the Walter Reed Army Institute of Research, a biomedical research laboratory of the US Department of Defense.